Germany's biotech investment has propelled a handful of companies onto the public markets a lot sooner than their US or UK counterparts. These German companies have followed aggressive acquisition strategies, most often buying into the US, sometimes using newly-minted Neuer Markt paper. Some are seeking through these acquisitions to both broaden their technology platform and acquire a product portfolio, hoping thereby to avoid the pitfalls of a narrow focus. It's too early to tell whether such a dual model will work. But the fact that Germany's young companies are finding their own approach to competing globally shows that the country's biotech initiative has already had some success.
by Melanie A. Senior
When Germany's politicians in the mid-nineties chose biotech to spearhead their initiative to turn the country into a model of...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Glenmark signals thrust on high margin products, while exiting tail end brands as part of efforts to emerge as a branded company. In-licensed assets like Brukinsa and Tevimbra are seen as pivotal to driving growth alongside.
Analysts lauded the 13-week weight-reduction rates Viking’s oral dual GLP-1/GIP agonist showed in Phase II, but the firm’s stock tumbled 42% due to high discontinuation rates.
The Sweden-based firm is set for talks with the FDA on the regulatory path for its MCT8 deficiency candidate.
The Danish firm's atopic dermatitis drug Adbry is performing well despite strong competition from Sanofi/Regeneron’s Dupixent.
The German company already had four eye disease candidates in Phase II development and sees promise in Palatin’s novel melanocortin receptor modulators.
The Sweden-based firm is set for talks with the FDA on the regulatory path for its MCT8 deficiency candidate.
Pfizer showed how to come out on top with investors during earnings season. Post strong sales growth – and avoid mentioning tariffs, most favored nation pricing or Medicare modernization impacts.
